SecurityORGS / Orgenesis, Inc. (68619K105)
IndustryPharmaceutical Preparations
Common Shares Outstanding14,569,359 shares (as of 2018-05-31)
Total Insiders6
Total Directors1
Total Officers1

Stock Insider Trading (from SEC Form 4)

Orgenesis, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ORGS / Orgenesis, Inc. insiders include Theodorus II SA, Theodorus SCA, Bultot Hugues, and Universite Libre de Bruxelles, Belenger Olivier, Caplan Vered.

Insider Roster

Insider Dir Off 10% Shares Owned
Caplan Vered CEO
X
Universite Libre de Bruxelles
408,792
Bultot Hugues Director
X 12,177,544
Theodorus II SA
2,952,358
Theodorus SCA
2,952,358
Belenger Olivier
5,904,716

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2017-11-17 4 Universite Libre de Bruxelles S D 1.8276 -204,396 408,792 747,108
2017-11-15 4 Universite Libre de Bruxelles S D 1.8276 -204,396 613,188 1,120,662
2017-11-13 4 Universite Libre de Bruxelles S D 1.8276 -204,396 817,584 1,494,217
2017-11-17 4 Bultot Hugues X D 356549.04 2,452,751 12,177,544
2017-01-16 4 Bultot Hugues J D -376,115 9,724,793
2017-10-11 4 Belenger Olivier I S I 0.25 -5,000,000 5,904,716 1,476,179
2017-10-11 4 Theodorus SCA S D 0.25 -2,500,000 2,952,358 738,090
2017-10-11 4 Theodorus SCA I S I 0.25 -2,500,000 2,952,358 738,090
2017-10-11 4 Theodorus II SA S D 0.25 -2,500,000 2,952,358 738,090
2017-10-11 4 Theodorus II SA I S I 0.25 -2,500,000 2,952,358 738,090
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

Orgenesis, Inc. - Overlooked Stock In The Gene Therapy Contract Development With R&D Pipeline

2018-06-03 seekingalpha
Overlooked specialty contract development and manufacturing stock in the exciting field of advanced cell therapy with a potential for an exponential upside. (184-3)